1. Introduction {#sec1-ijms-17-00457}
===============

Celiac disease (CD) is a chronic small intestinal immune-mediated enteropathy induced by dietary gluten in genetically predisposed people \[[@B1-ijms-17-00457]\]. Most patients are treated by a life-long gluten-free diet. It has a prevalence of \~1% in many populations worldwide \[[@B2-ijms-17-00457]\]. A genetic linkage study recognized HLA-DQ2 and HLA-DQ8 as the main genetic predisposing factors in the development of CD \[[@B3-ijms-17-00457]\]. However, a genetic-association study by Petronzelli *et al.* \[[@B4-ijms-17-00457]\] identified the effect of HLA contributing to CD was estimated to be only 36%, so non-HLA genes must be considered \[[@B5-ijms-17-00457]\].

Recently, a two-stage genome-wide association study (GWAS) found the contribution of the regions on chromosome 1q31 and 3q25 containing the regulator of G-protein signaling-1 (RGS1) gene and interleukin-12 A (IL12A) gene in the development of CD in European populations \[[@B6-ijms-17-00457]\]. Both of these genes are involved in the T helper cell type 1 (Th1) pathway, which are responsible for mucosal inflammation in active CD \[[@B7-ijms-17-00457]\]. RGS1, a member of the RGS protein family, activated GTPase by attenuating the signaling activity of G-proteins \[[@B8-ijms-17-00457]\]. Moratz *et al.* \[[@B9-ijms-17-00457]\] have reported RGS1 regulates chemokine receptor signaling and participates in B cell activation and proliferation. B cell differentiates into plasma cell and produce anti-tTG/antigliadin antibodies \[[@B10-ijms-17-00457]\]. By interacting with mtTG in the basement membrane region, tTG antibody might lead to enterocyte cytoskeleton and epithelial damage in CD \[[@B10-ijms-17-00457]\]. While IL12A encodes the IL12p35 submit, coincides with IL12p40 to form IL12p70. The heterodimeric IL-12 cytokine has a broad range of bioactivities on T and natural killer cells and it induces the production of interferon-γ (INF-γ) \[[@B11-ijms-17-00457]\]. Activated CD4^+^ T cell produces pro-inflammatory cytokines and results in Th1 response, which is dominantly regulated by INF-γ \[[@B12-ijms-17-00457]\]. Th-1 cytokines promote inflammatory effects and eventually induce enterocyte apoptosis in CD \[[@B13-ijms-17-00457]\].

Several studies have assessed the role for RGS1 rs2816316 (C/A) and IL12A rs17810546 (G/A) in CD development \[[@B6-ijms-17-00457],[@B7-ijms-17-00457],[@B14-ijms-17-00457],[@B15-ijms-17-00457],[@B16-ijms-17-00457],[@B17-ijms-17-00457],[@B18-ijms-17-00457]\]. However, the existing findings were inconsistent even among different ethnic populations in the same study. Thus, we perform a meta-analysis of all available studies to accurately estimate the relationships of RGS1 rs2816316/IL12A rs17810546 polymorphisms with CD risk.

2. Results {#sec2-ijms-17-00457}
==========

2.1. Eligible Studies and Characteristics {#sec2dot1-ijms-17-00457}
-----------------------------------------

According to the search strategy and inclusion criteria, seven studies involving 20 sub-study collections were identified about the associations of RGS1 and IL12A polymorphisms with CD \[[@B6-ijms-17-00457],[@B7-ijms-17-00457],[@B14-ijms-17-00457],[@B15-ijms-17-00457],[@B16-ijms-17-00457],[@B17-ijms-17-00457],[@B18-ijms-17-00457]\], of which 19 were conducted in Europe and one in America ([Table 1](#ijms-17-00457-t001){ref-type="table"}). The detailed steps of literature search are shown in [Figure 1](#ijms-17-00457-f001){ref-type="fig"}. Both RGS1 and IL12A polymorphisms were studied in 14,936 CD patients and 24,794 controls.

The detailed characteristics of the seven included studies are described in [Table 1](#ijms-17-00457-t001){ref-type="table"}. Genotype and allele distributions for each study are listed in [Table 2](#ijms-17-00457-t002){ref-type="table"} and [Table 3](#ijms-17-00457-t003){ref-type="table"}. Studies from Hunt *et al.* \[[@B6-ijms-17-00457]\] and Dubois *et al.* \[[@B15-ijms-17-00457]\] included three and twelve independent searches, respectively, which were estimated independently in our meta-analysis. Most of the studies had clear diagnostic criteria and control source, except the Irish Ethnic group by Dubois *et al.* \[[@B15-ijms-17-00457]\] that did not provide details from citation.

2.2. Risk of Bias Assessment {#sec2dot2-ijms-17-00457}
----------------------------

The results of bias assessment are presented in [Table S1](#app1-ijms-17-00457){ref-type="app"}. There are risks of bias in terms of ascertainment of CD ("unclear" in 1 out of 20 studies, 5.0%) and ascertainment of control ("unclear" in 1 out of 20 studies, 5.0%).

2.3. Genetic Association between RGS1 rs2816316 and CD Risk {#sec2dot3-ijms-17-00457}
-----------------------------------------------------------

Seven studies reported association between rs2816316 and CD, which involved 14,936 cases and 24,794 controls. Hardy--Weinberg equilibrium (HWE) test showed no study was considered to be disequilibrium. The pooled frequency of the minor allele C was 14.0% (95% CI = 13.6%--14.5%) in the CD groups and 17.5% (95% CI = 16.9%--18.2%) in the control groups. The population-attributable risk (PAR) for allele C was 4.19%. The odds ratio (OR) (C *vs.* A) was estimated by the fix-effect model with less across-study heterogeneity (*p* = 0.393, *I*^2^ = 5.2%), with a pooled OR of 0.77 (95% CI = 0.74--0.80) ([Figure 2](#ijms-17-00457-f002){ref-type="fig"}A). This result suggests that individuals carrying the C allele have a 23% lower risk of developing CD than those carrying the A allele. Harbord (*p* = 0.622) and Peters (*p* = 0.775) tests suggested no existence of publication bias. The results in [Figure 3](#ijms-17-00457-f003){ref-type="fig"}A indicated that the pooled OR (C *vs.* A) were stable without any publication bias. The sensitive analysis was performed to make sure that no individual study was entirely responsible for the pooled results. In [Table S2](#app1-ijms-17-00457){ref-type="app"}, none of the individual studies affect the final conclusion obviously.

Genotype frequency and estimated OR for each study were presented in [Figure 2](#ijms-17-00457-f002){ref-type="fig"}B,C. The OR~1~ (AC *vs.* AA) (*p* = 0.393, *I*^2^ = 5.2%) and the OR~2~ (CC *vs.* AA) (*p* = 0.943, *I*^2^ = 0.0%) were homogenous. The pooled ORs were estimated by the fix-effects model for OR~1~ (0.77, 95% CI = 0.74--0.81, *p* \< 0.001) and OR~2~ (0.57, 95% CI = 0.50--0.66, *p* \< 0.001), both of which were significant. Harbord and Peters tests in OR~1~ (*p* = 0.741, 0.910) and OR~2~ (*p* = 0.558, 0.553) as well as contour-enhanced funnel plot ([Figure 3](#ijms-17-00457-f003){ref-type="fig"}B,C) showed no publication bias and stable results. The λ = 0.487 (95% CI = 0.319--0.724) suggested a co-dominant model effect was most likely.

2.4. Genetic Association between IL12A rs17810546 and CD Risk {#sec2dot4-ijms-17-00457}
-------------------------------------------------------------

Seven studies reported association between rs17810546 and CD risk, involving 14,936 cases and 24,794 controls. By using HWE test, most studies were considered to be disequilibrium except for Sperandeo MP *et al.* \[[@B17-ijms-17-00457]\]. The pooled frequency of the minor allele G was 14.3% (95% CI = 13.0%--15.5%) in the CD groups and 10.9% (95% CI = 10.0%--11.7%) in the control groups. The PAR for allele G was 3.87%. The OR (G *vs.* A) was estimated by the fix-effect model with less across-study heterogeneity (*p* = 0.296, and *I*^2^ = 12.7%), with a pooled OR of 1.37 (95% CI = 1.31--1.43) ([Figure 4](#ijms-17-00457-f004){ref-type="fig"}A). This result suggests that individuals carrying the G allele have a 37% higher risk of developing CD than those carrying the A allele. Harbord and Peters tests (*p* = 0.281, 0.281) and contour-enhanced funnel plot ([Figure 3](#ijms-17-00457-f003){ref-type="fig"}D) suggested no publication bias and stable pooled results. The sensitive analysis results in [Table S3](#app1-ijms-17-00457){ref-type="app"} indicated none of the individual studies affect the final conclusion obviously.

Genotype frequency and estimated OR for each study were presented in [Figure 4](#ijms-17-00457-f004){ref-type="fig"}B,C. The OR~1~ (AG *vs.* AA) (*p* = 0.630, *I*^2^ = 0.0%) and OR~2~ (GG *vs.* AA) (*p* = 0.969, *I*^2^ = 0.0%) were homogenous. The pooled ORs were estimated by the fix-effects model for OR~1~ (1.37, 95% CI = 1.30--1.44, *p* \< 0.001) and OR~2~ (1.82, 95% CI = 1.55--2.14, *p* \< 0.001), both of which were significant. Harbord and Peters tests in OR~1~ (*p* = 0.678, 0.642) and OR~2~ (*p* = 0.971, 0.407) and contour-enhanced funnel plot ([Figure 3](#ijms-17-00457-f003){ref-type="fig"}E,F) showed no publication bias and stable results. The λ = 0.562 (95% CI = 0.398--0.816) also suggested a co-dominant model effect was most likely.

3. Discussion {#sec3-ijms-17-00457}
=============

In the past few years, several GWAS have identified 40 non-HLA genomic regions harboring 64 CD-associated candidate genes \[[@B15-ijms-17-00457]\]. However, non-HLA SNPs investigated in the present study are not regarded as strong markers of CD. To our knowledge, this is the first meta-analysis to reveal the associations of RGS1 (rs2816316) and IL12A (rs17810546) with CD and represents a pooled total of 14,936 cases and 24,794 controls across different ethnic populations. We found significant evidence for a modest decrease in CD risk associated with the minor C allele in rs2816316, and a modest increase in the minor G allele in rs17810546.

CD is a gluten-sensitive enteropathy and the only adopted treatment is a life-long gluten-free diet \[[@B19-ijms-17-00457]\]. However, the treatment renders ineffective in about 5% of cases whom could develop into enteropathy-associated T cell lymphoma \[[@B20-ijms-17-00457]\]. Thus, there is an urgent need to better understand the pathogenesis of CD, which could propel the development of pharmacologic agents in the treatment of CD. Our study identifies that major allele of rs2816316 and minor allele of rs17810546 are risk factors of CD, which suggests the potential role of RGS1 and IL12A in the treatment of CD. This finding should be confirmed by further biological and clinical studies.

The rs2816316 susceptibility allele is located on chromosome 1q31 and maps 8 kb from distal to the 5′ end of RGS1, which is involved in lymphocyte migration and can influence cell trafficking both in immune system development and exogenous infection \[[@B21-ijms-17-00457]\]. Interestingly, RGS1 has been recently shown to be associated with multiple sclerosis (MS) and type 1 diabetes (T1D), both of which are T cell-mediated diseases \[[@B12-ijms-17-00457],[@B22-ijms-17-00457]\]. The minor allele of rs2816316 is shared with MS and T1D, which suggested that the RGS1 might be an important T cell regulator. Study from Gibbons *et al.* \[[@B23-ijms-17-00457]\] has identified that RGS1 expression is significantly higher in T cells from human gut compared with peripheral blood, especially in intestinal inflammation. Actually, 15%\~20% of CD patients suffer from other autoimmune diseases \[[@B24-ijms-17-00457]\], which was strengthened by our study.

rs17810546 locates in a \~70-kb LD block, which is immediately 5′ of IL12A. Similar with the locus RGS1, IL12A has been reported with risk of MS and T1D, confirming the shared genetic factors among different autoimmune diseases \[[@B22-ijms-17-00457],[@B25-ijms-17-00457]\]. In addition, a meta-analysis by Kappen *et al.* \[[@B26-ijms-17-00457]\] identified the genome wide significance association between IL12A rs17810546 and Behcet's disease, which was also regarded as a Th1 mediated autoimmune disease. The minor allele of rs17810546 showed higher expression level of SCHIP1 gene, located in the same LD block with IL12A gene \[[@B7-ijms-17-00457]\]. IL12A encodes IL12 and induces the Th1 response in the perspective of the etiology of CD \[[@B27-ijms-17-00457]\]. Paajanen *et al.* \[[@B28-ijms-17-00457]\] has shown that the children with CD had the lower expression of IL12A mRNA, which suggested that the major allele of these loci might be a protective factor in CD. In our study, the rs17810546 GG homozygote and heterozygote AG have 82% and 37% increased risk of CD compared with the wide genotype AA, without evidence of between-study heterogeneity, which strengthening the pathogenic effect of IL12A minor allele in CD.

Although several previous studies have investigated the associations between CD risk and RGS1 or IL12A polymorphisms, our meta-analysis is more persuasive and well-documented. First, a total of 20 subsets were included to pool the results for each SNP, dramatically improving the power of statistical analysis. Second, the quality of each included study was desirable, since only studies satisfying the risk-of-bias score test could be included. Third, when we removed the studies one by one to detect the influence of a single study on the pooled OR of other studies, none of the individual studies affect the final conclusion obviously, suggesting the stability of our results. However, this retrospective analysis has several limitations. First, the number of included studies for each SNP is limited (seven studies for rs2816316 and 17810546 each). Nevertheless, this limitation is made up for by the relatively large sample sizes (14,936 cases and 24,794 controls). Second, controls in Italian population are not in Hardy--Weinberg equilibrium \[[@B17-ijms-17-00457]\]. In the sensitivity analysis, however, when this study was excluded, the results of disease associations were not altered. Third, since our study includes almost European ethnicities, the associations among other populations still need to be confirmed.

In summary, our meta-analysis indicates that RGS1 and IL12A are both associated with CD, especially in European populations. The associations should be validated by large-scale, well-designed epidemiological studies in the future.

4. Experimental Section {#sec4-ijms-17-00457}
=======================

4.1. Search Strategy {#sec4dot1-ijms-17-00457}
--------------------

Studies concerning the associations of RGS1 and IL12A polymorphisms with CD were searched from PubMed and Wed of Science by two reviewers independently. The updating date was 20 August, 2015. The detailed search strategy was as follows: (celiac disease or CD) and (polymorphism or SNP or rs2816316 or rs17810546) or (G-protein signaling-1 or RGS1) or (interleukin-12 A or IL12A). We only considered studies published in English and Chinese. We scanned the titles and abstracts of all relevant articles, manually examined reference lists for additional relevant publications and obtained the full texts of all possibly relevant studies. For multiple articles published with the same subjects, we selected the latest and most complete one.

4.2. Inclusion Criteria {#sec4dot2-ijms-17-00457}
-----------------------

Any human population-based association study was included only if it met all three criteria: (1) evaluation of the RGS1 (rs2816316) or IL12A (rs17810546) polymorphism and CD; (2) odds ratio (OR) and its 95% confidence interval (CI) was presented or could be calculated; and (3) there was clear diagnosis of CD. We contacted the authors to acquire indispensable information when their data were incomplete. Studies that did not provide data were excluded.

4.3. Data Extraction {#sec4dot3-ijms-17-00457}
--------------------

Summary data were extracted by two reviewers independently using a standardized form ([Table 1](#ijms-17-00457-t001){ref-type="table"}). The following information was extracted from each study: (1) name of first author; (2) year of publication; (3) country of population; (4) ethnicity of population; (5) genotyping method; (6) minor allele frequency (MAF) in controls; and (7) sample size of cases and controls. Genotype frequencies of each study and *p*-values for the Hardy--Weinberg equilibrium HWE test in control groups were extracted ([Table 2](#ijms-17-00457-t002){ref-type="table"} and [Table 3](#ijms-17-00457-t003){ref-type="table"}). If there was no detailed genotype data in a study, the theoretical frequency of genotypes was estimated from the MAF of polymorphisms. Any disagreement was resolved through consensus.

4.4. Risk of Bias Assessment {#sec4dot4-ijms-17-00457}
----------------------------

The quality of each study was assessed by two reviewers based on a risk-of-bias score for genetic association studies \[[@B29-ijms-17-00457]\]. The score considers 6 domains ([Table S1](#app1-ijms-17-00457){ref-type="app"}): information bias (ascertainment of outcome and gene), quality control for genotyping, population stratification, confounding bias, selective report of outcomes and HWE assessment in the control group. Each item was classified into "yes", "no" or "unclear", which represented low risk, high risk and insufficient information, respectively. Disagreement between the two reviewers was solved by a senior reviewer.

4.5. Statistical Analysis {#sec4dot5-ijms-17-00457}
-------------------------

All statistical analyses were performed on Stata 12.0. The association strength of RGS1 rs2816316 and IL12A rs17810546 with CD risk was assessed by OR and its 95%CI. *p* \< 0.05 was considered statistically significant in all tests, except for the heterogeneity test in which *p* \< 0.10 was used. The HWE of the genotype distribution in a control group was assessed by the *χ*^2^ goodness-of-fit test.

The statistical significance of the pooled OR was determined by the Mantel-Haenszel method. The across-study heterogeneity of allele effects was checked using a Q test and was quantified by *I*^2^ (*I*^2^ \< 25%, no; 25%--50%, moderate; 50%--75%, large; \>75%, extreme) \[[@B30-ijms-17-00457]\]. If heterogeneity was present (*i.e.*, Q test was significant), the cause of heterogeneity was explored by sensitivity analysis. A random-effect model was used if *I*^2^ \> 50%, otherwise, a fixed-effect model was used. The population-attributable risk PAR for mutant allele was calculated based on the results from a discrete-time model \[[@B31-ijms-17-00457]\].

We supposed that A and a were wild-type and mutant alleles, respectively; and AA, Aa and aa were common homozygous, heterozygous, and minor homozygous, respectively. The model-free approach was used to estimate the genotype effect, and two types of ORs for each study: aa *vs.* AA (OR~1~) and Aa *vs.* AA (OR~2~). The model of genetic effect, measured by the parameter lambda (λ: the ratio of logOR~2~ to logOR~1~), was then estimated by the model-free Bayesian approach. The λ represents the heterozygote effect as a proportion of the homozygote variant effect. Furthermore, the λ-value ranges from 0 to 1. We get information about the genetic mode of action as follows: λ = 0 suggests a recessive model (Aa + aa *vs.* AA); λ = 1 suggests a dominant model (AA + Aa *vs.* aa); λ = 0.5 suggests a co-dominant model (AA *vs.* aa; Aa *vs.* aa). λ \> 1 or λ \< 0 indicates a homozygous or heterosis model, although this is rare. The best genetic model, once identified, is used to collapse the three genotypes into two groups and re-pool the results. WinBugs 1.4.2 was used with vague prior to distributions for parameter estimation (*i.e.*, λ and OR). The models were run with a burn-in of 1000 iterations, followed by 10,000 iterations for parameter estimation.

The Harbord and Peters test were adopted to assess and quantify the publication bias. Additionally, a novel Contour-enhanced meta-analysis funnel plot method was used to combat publication biases \[[@B32-ijms-17-00457]\]. In the sensitive analysis, we removed the studies one by one to identify the influence of a single study on the pooled OR from other studies.

5. Conclusions {#sec5-ijms-17-00457}
==============

In conclusion, our study identified RGS1 rs2816316 was negatively associated with CD. In the other hand, IL12A rs17810546 was positively associated with CD. Further studies are required to elucidate how these variants contribute to the susceptibility of CD.
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![Flow chart showing the literature selection procedure used in this study: (**A**) RGS1 rs2816316; and (**B**) IL12A rs17810546.](ijms-17-00457-g001){#ijms-17-00457-f001}

![Meta-analysis forest plots of the correlations between RGS1 rs2816316 and celiac disease: (**A**) C *vs.* A; (**B**) AC *vs.* AA; and (**C**) CC *vs.* AA. The vertical dotted line and solid line represent the pooled odds ratio (OR) and the OR equals to 1, respectively. The horizontal solid lines mean the confidence intervals (CI) of OR in each population. And if the upper limit of OR exceed the top scale, arrow would replace the solid line. The size of solid squares corresponds to the weight of the study in the meta-analysis. The length of the hollow diamonds represent the CI of the pooled OR.](ijms-17-00457-g002){#ijms-17-00457-f002}

![Contour-enhanced funnel plot of IL2/IL21 and SH2B3 genes with CD: (**A**) RGS1 rs2816316 C *vs.* A; (**B**) RGS1 rs2816316 AC *vs.* AA; (**C**) RGS1 rs2816316 CC *vs.* AA; (**D**) IL12A rs17810546 G *vs.* A; (**E**) IL12A rs17810546 AG *vs.* AA; and (**F**) IL12A rs17810546 GG *vs.* AA.](ijms-17-00457-g003){#ijms-17-00457-f003}

![Meta-analysis forest plots of the correlations between IL12A rs17810546 and celiac disease: (**A**) G *vs.* A; (**B**) AG *vs.* AA; and (**C**) GG *vs.* AA. The vertical dotted line and solid line represent the pooled odds ratio (OR) and the OR equals to 1, respectively. The horizontal solid lines mean the confidence intervals (CI) of OR in each population. And if the upper limit of OR exceed the top scale, arrow would replace the solid line. The size of solid squares corresponds to the weight of the study in the meta-analysis. The length of the hollow diamonds represent the CI of the pooled OR.](ijms-17-00457-g004){#ijms-17-00457-f004}

ijms-17-00457-t001_Table 1

###### 

Characteristics of the included studies.

  Author                                   Year   Country       Ethnicity   Genotyping Method                MAF     Sample Size          
  ---------------------------------------- ------ ------------- ----------- -------------------------------- ------- ------------- ------ ------
  Van Heel \[[@B18-ijms-17-00457]\]        2007   UK            European    The Illumina Infinium II assay   0.174   0.123         778    1422
  Hunt \[[@B6-ijms-17-00457]\]             2008   UK            European    Infinium assay                   0.188   0.127         719    1561
  --                                       --     Ireland       European    GoldenGate assay                 0.187   0.130         416    957
  --                                       --     Netherlands   European    GoldenGate assay                 0.189   0.124         508    888
  Romanos \[[@B16-ijms-17-00457]\]         2009   Italy         European    Taqman probe                     0.166   0.067         538    598
  Coenen \[[@B14-ijms-17-00457]\]          2009   Netherlands   European    Taqman probe                     0.190   0.120         795    1683
  Dubois \[[@B15-ijms-17-00457]\]          2010   UK1           European    Illumina Hap300v1-1              0.182   0.118         737    2596
  --                                       --     UK2           European    Illumina 670-QuadCustom_v1       0.173   0.121         1849   4936
  --                                       --     Finland       European    Illumina 670-QuadCustom_v1       0.143   0.101         647    1829
  --                                       --     Netherlands   European    Illumina 670-QuadCustom_v1       0.188   0.118         803    846
  --                                       --     Italy         European    Illumina 670-QuadCustom_v1       0.169   0.067         497    543
  --                                       --     USA           American    Illumina GoldenGate              0.162   0.118         973    555
  --                                       --     Hungary       European    Illumina GoldenGate              0.158   0.113         965    1067
  --                                       --     Ireland       European    Illumina GoldenGate              0.182   0.133         597    1456
  --                                       --     Poland        European    Illumina GoldenGate              0.151   0.133         564    716
  --                                       --     Spain         European    Illumina GoldenGate              0.188   0.095         550    433
  --                                       --     Italy         European    Illumina GoldenGate              0.180   0.078         1010   804
  --                                       --     Finland       European    Illumina GoldenGate              0.162   0.113         259    653
  Sperandeo \[[@B17-ijms-17-00457]\]       2011   Italy         European    Taqman probe                     0.178   0.077         637    711
  Plaza-Izurieta \[[@B7-ijms-17-00457]\]   2011   Spain         European    TaqMan probe                     0.199   0.094         1094   540

MAF: minor allele frequency; Control_1: controls for RGS1 rs2816316; Control_2: controls for IL12A rs17810546.

ijms-17-00457-t002_Table 2

###### 

Genotype frequencies of rs2816316 in celiac disease (CD) and control groups and genotype effects in the meta-analysis.

  Author and Year                                     CD Group   Control Group   C *vs.* A   AC *vs.* AA   CC *vs.* AA   HWE *p* Value                                                               
  --------------------------------------------------- ---------- --------------- ----------- ------------- ------------- --------------- ------ ------------ ------ ------------ ------ ------------ -------
  Van Heel 2007 UK \[[@B18-ijms-17-00457]\]           581        183             14          970           409           43              0.74   0.63--0.89   0.75   0.61--0.91   0.54   0.29--1.00   0.988
  Hunt 2008 UK \[[@B6-ijms-17-00457]\]                545        162             12          1029          477           55              0.64   0.54--0.77   0.64   0.52--0.79   0.41   0.22--0.78   0.976
  Hunt 2008 Ireland \[[@B6-ijms-17-00457]\]           293        112             11          633           291           33              0.84   0.67--1.04   0.83   0.64--1.08   0.72   0.36--1.44   0.950
  Hunt 2008 Netherlands \[[@B6-ijms-17-00457]\]       376        122             10          584           272           32              0.70   0.56--0.86   0.70   0.54--0.89   0.49   0.24--1.00   0.962
  Romanos 2008 Italy \[[@B16-ijms-17-00457]\]         409        120             9           416           166           16              0.74   0.59--0.94   0.74   0.56--0.96   0.57   0.25--1.31   0.908
  Coenen 2009 Netherlands \[[@B14-ijms-17-00457]\]    588        191             16          1104          518           61              0.69   0.59--0.94   0.69   0.57--0.84   0.49   0.28--0.86   0.980
  Dubois 2010 UK1 \[[@B15-ijms-17-00457]\]            551        172             13          1737          773           86              0.70   0.59--0.82   0.70   0.58--0.85   0.48   0.26--0.86   0.999
  Dubois 2010 UK2 \[[@B15-ijms-17-00457]\]            1349       461             39          3376          1412          148             0.82   0.73--0.91   0.82   0.72--0.92   0.66   0.46--0.94   0.980
  Dubois 2010 Finland \[[@B15-ijms-17-00457]\]        495        142             10          1343          448           37              0.86   0.71--1.04   0.86   0.69--1.07   0.73   0.36--1.49   0.956
  Dubois 2010 Netherlands \[[@B15-ijms-17-00457]\]    595        192             16          558           258           30              0.70   0.58--0.84   0.70   0.56--0.87   0.50   0.27--0.93   0.978
  Dubois 2010 Italy \[[@B15-ijms-17-00457]\]          376        112             8           375           153           16              0.72   0.57--0.92   0.73   0.55--0.97   0.50   0.21--1.18   0.934
  Dubois 2010 USA \[[@B15-ijms-17-00457]\]            743        214             15          390           151           15              0.74   0.60--1.90   0.74   0.58--0.95   0.52   0.25--1.08   9.933
  Dubois 2010 Hungary \[[@B15-ijms-17-00457]\]        714        232             19          756           284           27              0.86   0.73--1.03   0.86   0.71--1.06   0.75   0.41--1.35   0.957
  Dubois 2010 Ireland \[[@B15-ijms-17-00457]\]        425        157             15          974           434           48              0.83   0.70--1.00   0.83   0.67--1.03   0.72   0.40--1.29   0.967
  Dubois 2010 Poland \[[@B15-ijms-17-00457]\]         412        140             12          516           184           16              0.96   0.77--1.19   0.95   0.74--1.23   0.94   0.44--2.01   0.932
  Dubois 2010 Spain \[[@B15-ijms-17-00457]\]          394        143             13          285           132           15              0.79   0.62--1.00   0.78   0.59--1.04   0.63   0.29--1.34   0.952
  Dubois 2010 Italy \[[@B15-ijms-17-00457]\]          721        265             24          541           237           26              0.84   0.70--1.00   0.84   0.68--1.03   0.69   0.39--1.22   0.994
  Dubois 2010 Finland \[[@B15-ijms-17-00457]\]        199        56              4           459           177           17              0.73   0.54--0.99   0.73   0.52--1.03   0.54   0.18--1.63   0.989
  Sperandeo 2011 Italy \[[@B17-ijms-17-00457]\]       463        166             8           488           193           30              0.77   0.62--0.94   0.91   0.71--1.16   0.28   0.13--0.62   0.054
  Plaza-Izurieta 2011 Spain \[[@B7-ijms-17-00457]\]   787        282             25          346           172           21              0.72   0.60--0.87   0.72   0.57--0.91   0.52   0.29--0.95   0.947
  Overall OR                                          --         --              --          --            --            --              0.77   0.74--0.80   0.77   0.74--0.81   0.57   0.50--0.67   --

HWE: Hardy--Weinberg equilibrium.

ijms-17-00457-t003_Table 3

###### 

Genotype frequencies of rs17810546 in CD and control groups and genotype effects in the meta-analysis.

  Author and Year                                     CD Group   Control Group   G *vs.* A   AG *vs.* AA   GG *vs.* AA   HWE *p* Value                                                                
  --------------------------------------------------- ---------- --------------- ----------- ------------- ------------- --------------- ------ ------------ ------ ------------ ------ ------------- -------
  Van Heel 2007 UK \[[@B18-ijms-17-00457]\]           546        211             20          1094          307           22              1.37   1.15--1.63   1.38   1.12--1.69   1.82   0.99--3.37    0.930
  Hunt 2008 UK \[[@B6-ijms-17-00457]\]                524        179             15          1190          346           25              1.17   0.98--1.40   1.17   0.95--1.45   1.36   0.71--2.61    0.979
  Hunt 2008 Ireland \[[@B6-ijms-17-00457]\]           277        125             14          724           216           16              1.51   1.21--1.88   1.51   1.17--1.96   2.29   1.10--4.75    0.980
  Hunt 2008 Netherlands \[[@B6-ijms-17-00457]\]       349        144             15          681           193           14              1.45   1.17--1.80   1.46   1.13--1.87   2.09   1.00--4.38    0.938
  Romanos 2008 Italy \[[@B16-ijms-17-00457]\]         427        105             6           521           75            3               1.68   1.25--2.26   1.71   1.24--2.36   2.44   0.61--9.81    0.865
  Coenen 2009 Netherlands \[[@B14-ijms-17-00457]\]    548        224             23          1303          355           24              1.50   1.27--1.78   1.50   1.23--1.82   2.28   1.28--4.07    0.974
  Dubois 2010 UK1 \[[@B15-ijms-17-00457]\]            515        202             20          2019          540           36              1.47   1.25--1.85   1.47   1.21--1.77   2.18   1.25--3.79    0.987
  Dubois 2010 UK2 \[[@B15-ijms-17-00457]\]            1339       469             41          3814          1050          72              1.27   1.14--1.42   1.27   1.12--1.44   1.62   1.10--2.39    0.977
  Dubois 2010 Finland \[[@B15-ijms-17-00457]\]        487        148             11          1478          332           19              1.35   1.11--1.63   1.35   1.09--1.68   1.76   0.83--3.72    0.941
  Dubois 2010 Netherlands \[[@B15-ijms-17-00457]\]    555        226             23          658           176           12              1.52   1.25--1.73   1.52   1.21--1.91   2.27   1.12--4.61    0.952
  Dubois 2010 Italy \[[@B15-ijms-17-00457]\]          392        99              6           473           68            2               1.77   1.30--2.41   1.76   1.25--2.46   3.62   0.73--18.04   0.788
  Dubois 2010 USA \[[@B15-ijms-17-00457]\]            720        234             19          432           116           8               1.21   0.97--1.51   1.21   0.94--1.56   1.42   0.62--3.28    0.946
  Dubois 2010 Hungary \[[@B15-ijms-17-00457]\]        674        265             26          839           214           14              1.54   1.28--1.84   1.54   1.25--2.45   2.31   1.20--4.46    0.932
  Dubois 2010 Ireland \[[@B15-ijms-17-00457]\]        398        179             20          1094          336           26              1.46   1.22--1.75   1.46   1.18--1.81   2.11   1.17--3.83    0.972
  Dubois 2010 Poland \[[@B15-ijms-17-00457]\]         390        158             16          538           165           13              1.32   1.06--1.64   1.32   1.02--1.70   1.70   0.81--3.57    0.932
  Dubois 2010 Spain \[[@B15-ijms-17-00457]\]          439        105             6           355           74            4               1.14   0.85--1.53   1.15   0.83--1.59   1.21   0.34--4.33    0.947
  Dubois 2010 Italy \[[@B15-ijms-17-00457]\]          825        175             9           683           116           5               1.24   0.98--1.57   1.25   0.97--1.61   1.49   0.50--4.47    0.975
  Dubois 2010 Finland \[[@B15-ijms-17-00457]\]        200        55              4           514           131           8               1.09   0.80--1.50   1.08   0.76--1.54   1.28   0.38--4.31    0.914
  Sperandeo 2011 Italy \[[@B17-ijms-17-00457]\]       526        106             5           610           92            9               1.20   0.91--1.57   1.34   0.99--1.81   0.64   0.21--1.93    0.029
  Plaza-Izurieta 2011 Spain \[[@B7-ijms-17-00457]\]   847        231             16          443           92            5               1.31   1.03--1.67   1.31   1.00--1.72   1.67   0.61--4.60    0.926
  Overall OR                                          --         --              --          --            --            --              1.37   1.31--1.43   1.37   1.30--1.44   1.82   1.55--2.14    --

HWE: Hardy--Weinberg equilibrium.

[^1]: These authors contributed equally to this work.
